Chronic Coronary Syndrome Real Practice and Guidelines

NCT06684366 | Active Not Recruiting

• 1 other identifier: Chronic coronary Syndrome
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

Evaluate Adherence to the 2019 ESC Guidelines and standard care protocols for managing patients with the chronic coronary syndrome within the center

Conditions

Coronary Arterial Disease (CAD)

Keywords

chronic coronary syndrome

Outcome Measures

Primary Outcomes (1)

• effect of revasculariztion strategies on chronic coronary syndrome patients

  6 months

Interventions

Statins (atorvastatin or simvastatin) DRUG

A resting transthoracic echocardiogram Non-invasive functional imaging for myocardial ischemia or coronary computed tomography angiography (CCTA) is recommended as the initial test for diagnosing CAD in symptomatic patients in whom obstructive CAD cannot be excluded by clinical assessment alone

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with angina and/or dyspnea, and suspected coronary artery disease. Patients with new onset of heart failure or reduced left ventricular function. Patients within 1 year after an acute coronary syndrome or recent revascularization. Patients beyond 1 year after initial diagnosis or revascularization. Patients with ANOCA (e.g., microvascular angina, vasospastic angina). Asymptomatic subjects referred for screening for coronary artery disease.

You may qualify if:

• Adult patients (18 years or older) with a confirmed or suspected diagnosis of CCS, fall within one of the following broad CCS categories:
• Patients with angina and/or dyspnea, and suspected coronary artery disease.
• Patients with new onset of heart failure or reduced left ventricular function.
• Patients within 1 year after an acute coronary syndrome or recent revascularization.
• Patients beyond 1 year after initial diagnosis or revascularization.
• Patients with ANOCA (e.g., microvascular angina, vasospastic angina).
• Asymptomatic subjects referred for screening for coronary artery disease.

You may not qualify if:

• Patients with a recent acute coronary syndrome (defined as those within 1 month of a diagnosis of unstable angina, non-ST-segment elevation myocardial infarction or ST-segment elevation myocardial infarction)

Sponsors & Collaborators

• Assiut University: lead

Study Sites (1)

Cardiology Department Assiut University

Asyut, Egypt

Location

MeSH Terms

Interventions

Hydroxymethylglutaryl-CoA Reductase Inhibitors; Atorvastatin; Simvastatin

Intervention Hierarchy (Ancestors)

Anticholesteremic Agents; Hypolipidemic Agents; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Enzyme Inhibitors; Lipid Regulating Agents; Therapeutic Uses; Pyrroles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heptanoic Acids; Fatty Acids; Lipids; Lovastatin; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: residuent doctor

Study Record Dates

• First Submitted: October 24, 2024
• First Posted: November 12, 2024
• Study Start: October 22, 2024
• Primary Completion: October 22, 2025
• Study Completion: October 22, 2025
• Last Updated: November 12, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)